The effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction  by Nakamura, Yoshinori et al.
Journal of Cardiology (2009) 54, 416—424
ORIGINAL ARTICLE
The effect of edaravone on plasma monocyte
chemoattractant protein-1 levels in patients
with acute myocardial infarction
Yoshinori Nakamura (MD)a,∗, Yoshihiro Yamada (MD)a,
Hideki Shimomura (MD)a, Yasuhiro Nagayoshi (MD)b,
Kenichi Tsujita (MD)b, Takuro Yamashita (MD)a, Masaya Fukuda (MD)b,
Keisuke Ohba (MD)b, Hisato Nako (MD)b, Yuji Ogura (MD)a,
Tadasuke Chitose (MD)a, Munetaka Yamaguchi (MD)a,
Takeshi Nagata (MD)a, Hirofumi Soejima (MD)b, Koichi Kaikita (MD)b,
Seigo Sugiyama (MD)b, Hisao Ogawa (MD, FJCC)b
a Fukuoka Tokushukai Medical Center, 4-5 Sukukita, Kasuga, Fukuoka 816-0864, Japan
b Department of Cardiovascular Medicine, Graduate School of Medical Sciences,
Kumamoto University, Kumamoto, Japan
Received 5 January 2009; received in revised form 21 June 2009; accepted 7 July 2009
Available online 20 August 2009
KEYWORDS
Antioxidants;
Free radicals;
Myocardial infarction;
Monocyte
chemoattractant
protein-1;
Reperfusion
Summary
Background: Monocyte chemoattractant protein-1 (MCP-1) plays an important role in
the pathogenesis of acute coronary syndrome. We have recently demonstrated that
the administration of edaravone before reperfusion attenuated reperfusion injury
in patients with acute myocardial infarction (AMI).
Methods: Plasma MCP-1 levels were measured in 45 consecutive patients with AMI
(edaravone group, n = 25; control group, n = 20). In the edaravone group, 30mg
edaravone was intravenously infused just before reperfusion. Plasma samples were
obtained before and at 24 h, 3, 5, 7, and 14 days after reperfusion. Cardiovascular
events were deﬁned as cardiac death, subacute thrombosis, or fatal arrhythmia.
Heart failure requiring rehospitalization was evaluated at 12 months after reperfu-
sion.
Results: Plasma MCP-1 levels were not different between the two groups before
reperfusion. Compared with the placebo group, the edaravone group had statisti-
cally lower maximum creatine kinase-MB levels (218± 31 IU/l versus 145± 21 IU/l,
p < 0.05) and plasma MCP-1 levels on day 3 after reperfusion (873± 118 pg/ml versus
516± 66 pg/ml, p < 0.05). Heart failure requiring rehospitalization occurred in four
∗ Corresponding author. Tel.: +81 92 573 6622; fax: +81 92 584 1991.
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patients in the control group, but did not occur in the edaravone group (p < 0.05). At
12 months after reperfusion, left ventricular ejection fraction was statistically higher
in the edaravone group than in the control group (62± 2% versus 54± 3%, p < 0.05).
Conclusion: Edaravone suppressed plasma MCP-1, improved left ventricular ejection
fraction, and reduced rehospitalization due to heart failure. Suppression of plasma
MCP-1 level by edaravone might induce better prognosis for AMI patients.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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occluded culprit lesion in the proximal segment
of a major coronary artery that persisted after
an intra-coronary nitrate injection. At ﬁrst, 50© 2009 Japanese Colleg
reserved.
ntroduction
yocardial reperfusion is necessary for the sal-
age and recovery of ischemic myocardium. Early
eperfusion has improved the clinical outcomes of
atients with acute myocardial infarction (AMI),
ut these beneﬁts are limited in some patients by
eperfusion injury [1—3].
Myocardial ischemia and reperfusion injury are
elieved to be associated with inﬂammatory reac-
ions involving various types of cells and cytokines
4]. Local and systemic inﬂammatory reactions
lay a key role in the extension of myocar-
ial tissue injury and adverse effects during left
entricular (LV) recovery [5]. Some experimen-
al studies have demonstrated the importance of
onocyte/macrophage inﬁltration after myocar-
ial infarction (MI) [6,7].
Monocyte chemoattractant protein-1 (MCP-1)
elongs to the CC chemokine subfamily with two
djacent cysteine residues and serves as a chemo-
actic and activating factor for the recruitment of
onocytes [8]. MCP-1 is secreted by various types of
ells, such as monocytes/macrophages, T lympho-
ytes, endothelial cells, vascular smooth muscle
ells, and myocytes [8—10]. Many experimental and
linical studies have demonstrated up-regulation
f MCP-1 after MI, with recruitment of mono-
ytes/macrophages to the ischemic myocardium
11—13].
The ability to control the activity of
acrophages or other cells by modulating the
roduction or inhibiting the action of MCP-1
ay lead to the design of new therapies to pre-
ent reperfusion injury. In an animal study, CC
hemokine receptor-2 (CCR-2) deﬁciency attenu-
ted oxidative stress and reduced infarct size after
yocardial ischemia-reperfusion [14]. Recently,
arge population studies demonstrated that MCP-1
ay have value as a biomarker for risk stratiﬁca-ion in both the initial and the chronic phases of
cute coronary syndromes, and support additional
nvestigation of MCP-1 (and CCR-2) as therapeutic
argets [15].
p
a
E
aEdaravone (3-methyl-1-phenyl-2-pyrazolin-5-
ne) has a low molecular weight (174.20 kDa),
s lipophilic, and is readily accessible to tissue
16,17]. Edaravone has the ability to scavenge
oxic free radicals; moreover, it has been shown
o inhibit vascular endothelial cell injury and to
nhibit brain edema caused by free radical-induced
ipid peroxidation [18]. We have already reported
hat the administration of edaravone just prior to
yocardial reperfusion attenuated both enzymatic
nfarct size and reperfusion arrhythmias in patients
ith AMI [19,20].
In the present study, we examined the efﬁcacy of
daravone on plasma MCP-1 levels in patients with
MI.
ethods
atients and study design
he present study was a randomized, placebo-
ontrolled, open-label study involving 50 patients
ith AMI admitted to our institution from Novem-
er 2002 to April 2006. The patients fulﬁlled the
ollowing inclusion criteria: (1) admission within
h of symptom onset; (2) coronary angiogra-
hy performed immediately after admission; and
3) emergency percutaneous coronary interven-
ion (PCI). The diagnosis of AMI was made on
he basis of chest pain persisting for ≥30min,
T-segment elevation of >0.2mV in ≥2 continu-
us leads on a standard 12-lead electrocardiogram
ECG), and elevation of serum creatine kinase
CK)-MB isoenzyme levels to more than twice
he upper limit of normal. During the study
eriod, 50 patients were enrolled that had anatients were randomly divided into an edar-
vone group (n = 25) or a control group (n = 25).
xclusion criteria included current use of edar-
vone, age <18 years, an inability to provide
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teristics were compared by using the chi-square
test. LVEF was compared by two-way ANOVA for418
informed consent, recent major surgery or trauma,
acute infection, antimicrobial treatment, corticos-
teroid treatment, chronic obstructive lung disease,
malignancy, renal insufﬁciency (deﬁned as serum
creatinine >1.2mg/dl), and altered hepatic func-
tion (deﬁned as serum aspartate aminotransferase
>50 IU/l, alanine aminotransferase >50 IU/l, and
total bilirubin >1.2mg/dl). Among the 50 patients,
ﬁve patients in the control group were excluded
from the dataset for the following reasons: loss
of blood sampling (three patients) and apparently
artifactual MCP-1 levels (two patients). Finally, 45
of 50 patients (edaravone group n = 25, control
group n = 20) were studied.
In the edaravone group, 30mg edaravone was
intravenously infused for 10min as soon as occlusion
of the infarct-related coronary artery was con-
ﬁrmed by coronary angiography; the control group
received the same volume of saline solution. The
study protocol was in agreement with the guide-
lines of the Ethics Committee at our institution, and
written informed consent was obtained from each
patient before enrollment.
Reperfusion therapy
Primary PCI was performed instantly, and thus,
coronary reperfusion was obtained immediately
after completion of the edaravone or saline
infusion. Pre-hospital thrombolysis, distal pro-
tection devices, and intra-coronary thrombolysis,
which have been shown to improve AMI prog-
nosis were not performed in the present study.
In all patients, coronary stents were success-
fully implanted at the culprit lesion to prevent
acute coronary occlusion, which is likely to occur
after balloon angioplasty alone. The use of con-
comitant medications was similar between the
two groups. Patients were routinely treated with
aspirin (100—200mg/day, indeﬁnitely) and ticlo-
pidine (200mg/day for 2 weeks after coronary
stenting). In both groups, an initial bolus of
130U/kg heparin was given; additional boluses
of heparin were administered during the proce-
dure to maintain an activated clotting time of
300 s.
Determination of infarct size and
monitoring of reperfusion arrhythmiasBlood samples were obtained before and imme-
diately after reperfusion, and then at 6, 12, 18,
24 h and 3, 5, 7, and 14 days after reperfusion.
Serum biomarkers were measured by using a stan-
dard enzymatic method. We monitored the ECGs
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ontinuously and compared the incidence of reper-
usion arrhythmias such as ventricular tachycardia
r ventricular ﬁbrillation between the two groups.
wo-dimensional echocardiography for analysis of
V ejection fraction (LVEF) was performed by car-
iologists immediately after reperfusion therapy
acute phase), 2 weeks after admission (chronic
hase), and 12 months after reperfusion therapy.
VEF was calculated by the modiﬁed Simpson’s rule
lgorithm.
ardiovascular events
e deﬁned cardiovascular events during admis-
ion as any of the following: (1) cardiac death;
2) subacute thrombosis; or (3) ventricular tachy-
ardia. Cardiac death was deﬁned as death from
I. Subacute stent thrombosis was deﬁned as MI
r angiographic occlusion of a stent, with throm-
olysis in myocardial infarction (TIMI) ﬂow 0—1
fter the ﬁrst 24 h and during the ﬁrst month.
entricular tachycardia was deﬁned as ≥6 con-
ecutive premature ventricular contractions. Heart
ailure requiring rehospitalization was evaluated at
2 months after reperfusion therapy.
erial determination of plasma MCP-1 levels
lasma levels of MCP-1 antigen were measured
sing a commercially available enzyme-linked
mmunosorbent assay kit (MCP-1: HyCult Biotech-
ology bv, Uden, the Netherlands). The intra-assay
nd inter-assay coefﬁcients of variation at an MCP-
antigen level of 630 pg/ml were 10.3% and 4.9%,
espectively.
tatistical analysis
ll data are expressed as the mean± SEM. Compar-
sons of age, body mass index, levels of hemoglobin,
erum cholesterol, triglyceride, hemoglobin A1c,
-reactive protein, CK, CK-MB, brain natriuretic
eptide (BNP), duration from onset to reperfu-
ion and reperfusion to maximum (Max) CK-MB
etween the two groups were performed with
one-way analysis of variance (ANOVA) followed
y Scheffé’s test and the other baseline charac-epeated measures. When the results were sig-
iﬁcant, the signiﬁcance level for correlations is
iven after applying the Bonferroni method. p-
alues <0.05 were considered to be statistically
igniﬁcant.
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omparison of clinical characteristics
he baseline clinical characteristics of the study
ubjects are shown in Table 1. There were no signif-
cant differences in age, male gender, coronary risk
actors, prior MI, history of congestive heart fail-
re (CHF), atrial ﬁbrillation, multivessel disease,
emoglobin, lipid proﬁles, and the rate of anterior
I between the two groups. There were also no dif-
erences in duration from onset to reperfusion and
eperfusion to Max CK-MB between the two groups.
he rate of Forrester classiﬁcation II—IV was statis-
ically higher in the edaravone group than in the
ontrol group (p < 0.05). There were no signiﬁcant
a
o
l
g
s
Table 1 Patient characteristics in the control and edaravo
Variables Control gr
Age (years) 66±
Male gender 15 (75
Hypertension 17 (85
Diabetes mellitus 9 (45
Smoking 10 (50
Body mass index (kg/m2) 24.8± 0
Prior MI 2 (10
History of CHF 1 (5
Atrial ﬁbrillation 1 (5
Number of diseased vessels
≤1 8 (40
≥2 12 (60
Hemoglobin (g/dl) 13.9± 1
Total cholesterol (mg/dl) 213±
HDL cholesterol (mg/dl) 50±
LDL cholesterol (mg/dl) 125±
Triglyceride (mg/dl) 186±
Hemoglobin A1c (%) 6.5± 0
C-reactive protein (mg/dl) 0.3± 0
Killip classiﬁcation at admission
Class I/class II-IV (II/III/IV) 17/3 (2/0/
Forrester classiﬁcation at admission
Subset I/II-IV (II/III/IV) 12/8 (8/0/
Anterior myocardial infarction 12 (60
Duration from onset to reperfusion (h) 3.3± 1
Duration from reperfusion to Max CK-MB (h) 7.2± 0
Concomitant medications
Statins 9 (45
-Blockers 6 (30
ACE inhibitors/ARBs 18 (90
Calcium-channel blockers 4 (20
Nitrates 0 (0
Data are presented as mean± SEM or numbers of patients (percenta
receptor blockers; CHF, congestive heart failure; HDL, high-density li
creatine kinase-MB; MI, myocardial infarction.dial infarction patients 419
ifferences in the use of pharmacotherapy, includ-
ng statins, angiotensin-converting enzyme (ACE)
nhibitors, angiotensin II receptor blockers (ARBs),
-blockers, calcium-channel blockers, or nitrates
etween the two groups.
omparison of enzymatic infarct size and
ardiac events during admission
n all patients, primary PCI was performed on the
ulprit lesion and successful reperfusion (deﬁned
s the achievement of TIMI grade 3 ﬂow) was
btained within 6 h of symptom onset. Max CK-MB
evels were signiﬁcantly lower in the edaravone
roup than in the control group (145± 21 IU/l ver-
us 218± 31 IU/l, p < 0.05) as shown in Table 2. All
ne groups.
oup (n = 20) Edaravone group (n = 25) p-Value
3 64± 2 0.530
%) 17 (68%) 0.745
%) 14 (56%) 0.054
%) 7 (28%) 0.348
%) 13 (52%) >0.99
.7 23.9± 0.6 0.224
%) 1 (4%) 0.577
%) 0 (0%) 0.444
%) 1 (4%) >0.99
%) 10 (40%) >0.99
%) 15 (60%)
.9 14.3± 1.5 0.504
10 211± 7 0.855
3 53± 2 0.519
8 119± 6 0.543
25 202± 33 0.712
.5 5.7± 0.2 0.143
.1 0.6± 0.3 0.422
1) 18/7 (6/0/1) 0.473
0) 6/19 (19/0/0) 0.031
%) 16 (64%) >0.99
.1 3.3± 1.8 0.973
.6 7.4± 0.6 0.854
%) 14 (56%) 0.554
%) 8 (32%) >0.99
%) 25 (100%) 0.192
%) 5 (20%) >0.99
%) 0 (0%)
ge). ACE, angiotensin-converting enzyme; ARBs, angiotensin-II
poprotein; LDL, low-density lipoprotein; Max CK-MB, maximum
420 Y. Nakamura et al.
Table 2 Comparison of serologic and functional ﬁndings, and clinical outcomes.
Variables Control group (n = 20) Edaravone group (n = 25) p-Value
Plasma MCP-1 levels at admission (pg/mg) 839± 55 817± 104 0.864
Max CPK (IU/l) 3006± 440 2238± 335 0.164
Max CK-MB (IU/l) 218± 31 145± 21 0.048
Left ventricular ejection fraction (%)
Acute phase 51± 3 57± 2 0.035
Chronic phase (2 weeks) 55± 2 59± 2 0.136
12 months after reperfusion therapy 54± 3 62± 2 0.022
Cardiovascular events
Composite endpoint during admission 5 2 0.214
Subacute thrombosis 1 0 0.444
Cardiac death 1 0 0.444
Ventricular tachycardia 3 2 0.642
Heart failure requiring rehospitalization within 4 0 0.029
K, cr
f
g
i
A12 months after reperfusion therapy
Data are presented as mean± SEM or numbers of patients. CP
Max, maximum; MCP-1, monocyte chemoattractant protein-1.
patients had systolic or diastolic dysfunction. Five
of twenty patients had LVEF < 50% in the control
group, and 7 of 25 patients in the edaravone group.
There were no signiﬁcant differences in the rate
of LVEF < 50% between the two groups (p > 0.99).
Some improvement in LVEF was observed during
the acute phase in the edaravone group (57± 2%
versus 51± 3%, p < 0.05). At 2 weeks after reper-
s
t
C
i
Figure 1 Serial changes in plasma monocyte chemoattractan
control (n = 20) groups. Plasma MCP-1 levels tended to be lowe
the experimental course. The plasma MCP-1 levels on day 3 a
edaravone group than in the control group. *p < 0.05 vs controeatine phosphokinase; CK-MB, creatine kinase-MB isoenzyme;
usion therapy, LVEF was ameliorated in the two
roups, but differences in LVEF disappeared dur-
ng the chronic phase (59± 2% versus 55± 2%, NS).
t 12 months after reperfusion therapy, LVEF was
tatistically higher in the edaravone group than in
he control group (62± 2% versus 54± 3%, p < 0.05).
ardiovascular events during admission were higher
n the control group (ﬁve patients) than in the
t protein-1 (MCP-1) levels in the edaravone (n = 25) and
r in the edaravone than in the control group throughout
fter reperfusion therapy were statistically lower in the
l group.
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Table 3 Comparison of serologic and functional ﬁndings.
Variables Heart failure requiring
rehospitalization (+)
group (n = 4)
Heart failure requiring
rehospitalization (−)
group (n = 40)
p-Value
Plasma MCP-1 levels on day 3 (pg/mg) 1031± 91 629± 57 0.029
BNP (pg/ml)
Chronic phase (2 weeks ) 437± 203 212± 43 0.108
Left ventricular ejection fraction (%)
Acute phase 53± 5 55± 1 0.646
Chronic phase (2 weeks ) 45± 4 58± 1 0.007
12 months after reperfusion therapy 32± 1 60± 1 <0.001
The use of diuretic drug within 12 months after 3 4 0.010
NP, b
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Data are presented as mean± SEM or numbers of patients. B
protein-1.
daravone group (two patients). Three patients
xperienced ventricular tachycardia in the control
roup, as did two patients in the edaravone group.
ne patient experienced subacute thrombosis and
ne experienced cardiac death in the control group.
n the edaravone group, no patients suffered from
ny adverse effects from the use of edaravone, such
s renal insufﬁciency or altered hepatic function.
erial changes in plasma MCP-1 levels
he plasma MCP-1 levels were not different
etween the two groups before reperfusion; how-
ver, the plasma MCP-1 levels on day 3 after reper-
usion were statistically lower in the edaravone
roup than in the control group (516± 66 pg/ml ver-
us 873± 118 pg/ml, p < 0.05) (Fig. 1). Moreover,
lasma MCP-1 levels tended to be lower in the edar-
vone group than in the placebo group throughout
he experimental course.
ong-term follow-up and heart failure
equiring rehospitalization
t 12 months after reperfusion therapy, 44 of 45
atients were analyzed because one patient died
n the acute phase. Heart failure requiring rehos-
italization occurred in four patients in the control
roup, but did not occur in the edaravone group
t 12 months after reperfusion therapy (p < 0.05).
e subdivided the 44 AMI patients into two groups
ased on the presence (n = 4) or absence (n = 40)
f heart failure requiring rehospitalization. The
roup with heart failure requiring rehospitalization
as deﬁned as R (+) group and the group with-
ut heart failure requiring rehospitalization as R
−) group. Plasma MCP-1 levels on day 3 in the R
+) group were statistically higher than in the R
s
d
ﬁ
d
arain natriuretic peptide; MCP-1, monocyte chemoattractant
−) group (1031± 91 pg/ml versus 629± 57 pg/ml,
= 0.029) (Table 3). BNP levels in the R (+) group at
weeks after reperfusion therapy and rehospital-
zation were higher (437± 203 pg/ml at 2 weeks,
126± 317 pg/ml at rehospitalization) than in the
(−) group (212± 43 pg/ml, at 2 weeks). LVEF at
weeks and at 12 months after reperfusion ther-
py were statistically lower in the R (+) group
han in the R (−) group (45± 4% versus 58± 1%
t 2 weeks, p < 0.01, 32± 1% versus 60± 1% at 12
onths, p < 0.001). The use of diuretic drugs within
2 months after reperfusion therapy was needed 3
f 4 patients in the R (+) group, and 4 of 40 patients
n the R (−) group (p = 0.010). The triggers of heart
ailure were associated with restenosis and arrhyth-
ias.
iscussion
arly reperfusion has improved the clinical out-
omes of patients with AMI. We have recently
emonstrated that the administration of edaravone
ust before myocardial reperfusion attenuated both
nzymatic infarct size and reperfusion arrhythmias
n patients with AMI [19,20]. However, the detailed
echanism underlying the cardioprotective effect
ith edaravone treatment remains unclear.
Many experimental and clinical studies have
emonstrated up-regulation of MCP-1 after MI,
ith recruitment of monocytes/macrophages to the
schemic myocardium [11—13]. Hayashidani et al.
eported that an anti-MCP-1 gene therapy improved
urvival rate of mice as well as attenuated LV cavity
ilatation and contractile dysfunction, interstitial
brosis, recruitment of macrophages, and myocar-
ial gene expression of tumor necrosis factor-,
nd transforming growth factor- [21]. Thus, MCP-1
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appears to be involved in myocardial ischemia-
reperfusion injury. In this study, we veriﬁed the
clinical beneﬁt of edaravone on infarct size and car-
diovascular events and focused on plasma MCP-1
levels.
Our study indicated that the administration of
edaravone just before reperfusion in AMI reduced
plasma MCP-1 levels and cardiac damage (reduc-
tion of Max CK-MB and maintenance of cardiac
function: EF). Plasma MCP-1 levels in the edar-
avone group were suppressed more than in the
placebo group from day 1 to 14. A signiﬁ-
cant difference in MCP-1 levels between the two
groups was observed by day 3. Murakami et al.
reported a late increase in plasma MCP-1 levels
in subacute phase in AMI patients [22]. A sim-
ilar tendency was observed in our study. This
ﬁnding is considered to be due to the accumu-
lation of monocytes and macrophages within the
infarcted myocardium in response to subsequent
repair processes. Several studies have reported
that MCP-1 also strongly promotes angiogenesis in
the ischemic tissue [23—25]. Hayasaki et al. used
immunohistochemical staining and showed that the
number of macrophages in reperfused myocardium
increased 6 h after reperfusion and peaked on day
3. Moreover, by blocking MCP-1 receptors, CCR-2
deﬁciency attenuated the migration and activa-
tion of macrophages during the initial reperfusion
phase in AMI and reduced myocardial ischemia-
reperfusion injury [14]. Accordingly, we consider
that edaravone inhibits the recruitment and attach-
ment of monocytes/macrophages to reperfused
myocardium during the ﬁrst 3 days after AMI and
reduces MCP-1 production in that tissue. That
mechanism might contribute to favorable results in
AMI patients.
In the clinical setting, we have previously
investigated the correlation between reactive
oxygen species (ROS) generation and coronary
heart disease. Previous studies have demonstrated
that oxidative stress markers, including plasma
thioredoxin levels, urinary biopyrrins, 8-hydroxy-2′-
deoxyguanosine, 8-epi prostaglandin (PG) F2alpha
excretion, and 8-epi PGF2alpha levels from the
great cardiac vein were elevated in patients
with AMI [26—32]. These oxidative stress mark-
ers may predict subsequent cardiovascular events.
Edaravone administration also reduced serum
thioredoxin levels during the clinical course of AMI
in the previous study. Serum thioredoxin levels after
reperfusion therapy were signiﬁcantly lower in the
edaravone group than in the placebo group and
especially in the subacute phase, serum thioredoxin
levels remained at lower levels in the edaravone
group than in the placebo group [20]. A similar ten-
W
T
t
fY. Nakamura et al.
ency was also observed in the present study (data
ot shown).
Meanwhile, in patients who needed to be rehos-
italized with heart failure, LVEF at discharge and
t 12 months after reperfusion therapy was statis-
ically lower than in patients who did not need to
e rehospitalized in our study. In addition, plasma
CP-1 levels on day 3 were statistically higher
n patients who needed to be rehospitalized with
eart failure. Higher plasma MCP-1 levels on day
might induce lower LVEF and rehospitalization
ue to heart failure at 12 months after reper-
usion therapy. Furthermore, LVEF at 12 months
fter reperfusion was statistically higher in the
daravone group than in the control group and
eart failure requiring rehospitalization occurred
uring the chronic phase in the control group
ut not in the edaravone group. A recent study
emonstrated elevated circulating levels of CC
hemokines in patients with CHF [33]. The increase
n CC chemokine levels was independent of the
ause of heart failure, but particularly high MCP-1
evels were found in patients with coronary artery
isease. The raised MCP-1 levels in serum from CHF
atients enhanced spontaneous ROS generation in
onocytes. This enhancement increased apopto-
is of cardiomyocytes in patients with severe heart
ailure [34,35]. Increased ROS generation in mono-
ytes may further enhance the synthesis of MCP-1
n various cells through an autocrine mechanism
36]. From these ﬁndings, we suggest that edar-
vone inhibits MCP-1 production, thereby reducing
ardiac damage in myocardial tissue. This mech-
nism might have contributed to the reduction in
ehospitalization due to heart failure in the edar-
vone group.
The limitations of the present study include the
elatively small sample size and open-label study
ecause some patients were excluded from the
ataset for loss of blood samples and apparently
rtifactual MCP-1 levels. Thus, further investiga-
ion is required to clarify the impact of reduction
f plasma MCP-1 levels on cardiovascular events.
In conclusion, edaravone suppressed plasma
CP-1, improved LVEF, and reduced rehospitaliza-
ion due to heart failure after reperfusion therapy.
uppression of plasma MCP-1 levels by edaravone
ight induce better prognosis for AMI patients.
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